Ursolic acid, a naturally occurring triterpenoid, demonstrates anticancer activity on human prostate cancer cells

被引:90
作者
Kassi, E.
Papoutsi, Z.
Pratsinis, H.
Aligiannis, N.
Manoussakis, M.
Moutsatsou, P.
机构
[1] Univ Athens, Sch Med, Dept Biol Chem, Athens 11527, Greece
[2] NCSR Demokritos, Inst Biol, Lab Cell Proliferat & Ageing, GR-15310 Athens, Greece
[3] Univ Athens, Dept Pharm, Lab Pharmacognosy, GR-15771 Athens, Greece
[4] Univ Athens, Sch Med, Lab Pathophysiol, Athens 11527, Greece
关键词
LNCaP cells; dexamethasone; RU486; ursolic acid; prostate cancer;
D O I
10.1007/s00432-007-0193-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose Glucocorticoids are widely used as adjuvant therapy in hormonal refractory prostate cancer; their therapeutic role, however, remains unclear. Ursolic acid, a natural triterpene, structurally similar to dexamethasone, exhibits antitumor effects in various cell types. Our main objective was to investigate the effects of ursolic acid on cell viability, apoptosis and bcl-2 protein, in human hormone refractory and androgen-sensitive prostate cancer cells. Methods The ursolic acid-induced changes in cell viability, apoptosis and bcl-2 protein were examined in human hormone refractory prostate cancer PC-3 cells and androgen-sensitive LNCaP cells, by MTT assay, flow cytometry and western blot analysis, respectively. Results Ursolic acid inhibited significantly the cell viability and induced apoptosis in PC-3 cells at 55 mu M and in LNCaP cells at 45 mu M associated with a downregulation of bcl-2 protein. Conclusions The antiproliferative and apoptotic effects of ursolic acid in PC-3 and LNCaP cells implicate its potential therapeutic use for the treatment of hormone refractory and androgen-sensitive prostate cancer. The downregulation of bcl-2 may be one of the molecular mechanisms via which it induces apoptosis in PC-3 and LNCaP cells.
引用
收藏
页码:493 / 500
页数:8
相关论文
共 35 条
[21]   A glucocorticoid-responsive mutant androgen receptor exhibits unique ligand specificity: Therapeutic implications for androgen-independent prostate cancer [J].
Krishnan, AV ;
Zhao, XY ;
Swami, S ;
Brive, L ;
Peehl, DM ;
Ely, KR ;
Feldman, D .
ENDOCRINOLOGY, 2002, 143 (05) :1889-1900
[22]  
Liang YY, 2002, INT J ONCOL, V21, P1259
[23]   GROWTH-INHIBITION OF ANDROGEN-INSENSITIVE HUMAN PROSTATE CARCINOMA-CELLS BY A 19-NORSTEROID DERIVATIVE AGENT, MIFEPRISTONE [J].
LIN, MF ;
KAWACHI, MH ;
STALLCUP, MR ;
GRUNBERG, SM ;
LIN, FF .
PROSTATE, 1995, 26 (04) :194-204
[24]   Potential mechanism for the effects of dexamethasone on growth of androgen-independent prostate cancer [J].
Nishimura, K ;
Nonomura, N ;
Satoh, E ;
Harada, Y ;
Nakayama, M ;
Tokizane, T ;
Fukui, T ;
Ono, Y ;
Inoue, H ;
Shin, M ;
Tsujimoto, Y ;
Takayama, H ;
Aozasa, K ;
Okuyama, A .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2001, 93 (22) :1739-1746
[25]  
Nishimura K, 2000, CANCER, V89, P2570, DOI 10.1002/1097-0142(20001215)89:12<2570::AID-CNCR9>3.0.CO
[26]  
2-H
[27]  
NOVOTNY L, 2001, MINIREVIEW NEOPLASMA, V78, P2041
[28]  
Ovesná Z, 2004, NEOPLASMA, V51, P327
[29]   MEDIATION OF GLUCOCORTICOID RECEPTOR FUNCTION BY TRANSFORMING GROWTH-FACTOR-BETA-I EXPRESSION IN HUMAN PC-3 PROSTATE-CANCER CELLS [J].
REYESMORENO, C ;
FRENETTE, G ;
BOULANGER, J ;
LAVERGNE, E ;
GOVINDAN, MV ;
KOUTSILIERIS, M .
PROSTATE, 1995, 26 (05) :260-269
[30]   Effect of prednisone on prostate-specific antigen in patients with hormone-refractory prostate cancer [J].
Sartor, O ;
Weinberger, M ;
Moore, A ;
Li, AL ;
Figg, WD .
UROLOGY, 1998, 52 (02) :252-256